These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 14594439

  • 1. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF, Plosker GL.
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G, Danchenko N, Despiegel N, Marteau F.
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [Abstract] [Full Text] [Related]

  • 4. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 5. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

  • 6. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG, Toumi I, Hemels ME.
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [Abstract] [Full Text] [Related]

  • 7. Escitalopram: a review of its use in the management of major depressive disorder.
    Murdoch D, Keam SJ.
    Drugs; 2005 Apr; 65(16):2379-404. PubMed ID: 16266205
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K.
    J Med Econ; 2010 Apr; 13(3):516-26. PubMed ID: 20698748
    [Abstract] [Full Text] [Related]

  • 9. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J, Stage KB, Damsbo N, Le Lay A, Hemels ME.
    Nord J Psychiatry; 2007 Apr; 61(2):100-8. PubMed ID: 17454724
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL, Montgomery S, Francois C.
    Pharmacoeconomics; 2005 Apr; 23(2):155-67. PubMed ID: 15748090
    [Abstract] [Full Text] [Related]

  • 11. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM, Fernandez JL.
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [Abstract] [Full Text] [Related]

  • 12. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
    Malone DC.
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
    [Abstract] [Full Text] [Related]

  • 13. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW, Valuck R, Saseen J, MacFall HM.
    CNS Drugs; 2004 Jul; 18(13):911-32. PubMed ID: 15521793
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 15. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG, Toumi I, Hemels ME.
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on escitalopram in the management of major depressive disorder.
    Murdoch D, Keam SJ.
    CNS Drugs; 2006 Apr; 20(2):167-70. PubMed ID: 16478291
    [Abstract] [Full Text] [Related]

  • 17. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
    Kongsakon R, Bunchapattanasakda C.
    J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
    Kulp W, von der Schulenburg JM, Greiner W.
    Eur J Health Econ; 2005 Dec; 6(4):317-21. PubMed ID: 16267659
    [Abstract] [Full Text] [Related]

  • 19. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J, Goa KL.
    CNS Drugs; 2003 Dec; 17(5):343-62. PubMed ID: 12665392
    [Abstract] [Full Text] [Related]

  • 20. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T.
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.